BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 17806050)

  • 21. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.
    Wozniak A; Scioscia N; García PC; Dale JB; Paillavil BA; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM
    Microbiol Immunol; 2018 Jun; 62(6):395-404. PubMed ID: 29704396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein.
    Georgousakis MM; Hofmann A; Batzloff MR; McMillan DJ; Sriprakash KS
    Vaccine; 2009 Nov; 27(48):6799-806. PubMed ID: 19729086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of group a streptococcal anti-M type-specific antibody in sera of rheumatic fever patients after 45 years.
    Bencivenga JF; Johnson DR; Kaplan EL
    Clin Infect Dis; 2009 Oct; 49(8):1237-9. PubMed ID: 19761409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies in the development of vaccines to prevent infections with group A streptococcus.
    Good MF; Batzloff MR; Pandey M
    Hum Vaccin Immunother; 2013 Nov; 9(11):2393-7. PubMed ID: 23863455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular biology of Group A
    Brahmadathan NK
    Indian J Med Microbiol; 2017; 35(2):176-183. PubMed ID: 28681803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
    Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
    Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999.
    O'Brien KL; Beall B; Barrett NL; Cieslak PR; Reingold A; Farley MM; Danila R; Zell ER; Facklam R; Schwartz B; Schuchat A
    Clin Infect Dis; 2002 Aug; 35(3):268-76. PubMed ID: 12115092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
    Chuan YP; Wibowo N; Connors NK; Wu Y; Hughes FK; Batzloff MR; Lua LH; Middelberg AP
    Biotechnol Bioeng; 2014 Jun; 111(6):1062-70. PubMed ID: 24338691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
    Pandey M; Mortensen R; Calcutt A; Powell J; Batzloff MR; Dietrich J; Good MF
    J Immunol; 2016 Apr; 196(8):3364-74. PubMed ID: 26969753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
    Mannam P; Jones KF; Geller BL
    Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
    Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
    J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.
    Bauer MJ; Georgousakis MM; Vu T; Henningham A; Hofmann A; Rettel M; Hafner LM; Sriprakash KS; McMillan DJ
    Vaccine; 2012 Mar; 30(12):2197-205. PubMed ID: 22265945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
    Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
    J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation.
    Moyle PM; Olive C; Ho MF; Good MF; Toth I
    J Med Chem; 2006 Oct; 49(21):6364-70. PubMed ID: 17034142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Group A streptococcal emm type prevalence among symptomatic children in Cape Town and potential vaccine coverage.
    Engel ME; Muhamed B; Whitelaw AC; Musvosvi M; Mayosi BM; Dale JB
    Pediatr Infect Dis J; 2014 Feb; 33(2):208-10. PubMed ID: 23934204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines.
    Simerska P; Abdel-Aal AB; Fujita Y; Moyle PM; McGeary RP; Batzloff MR; Olive C; Good MF; Toth I
    J Med Chem; 2008 Mar; 51(5):1447-52. PubMed ID: 18278857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemic of group A Streptococcus M/emm59 causing invasive disease in Canada.
    Tyrrell GJ; Lovgren M; St Jean T; Hoang L; Patrick DM; Horsman G; Van Caeseele P; Sieswerda LE; McGeer A; Laurence RA; Bourgault AM; Low DE
    Clin Infect Dis; 2010 Dec; 51(11):1290-7. PubMed ID: 21034198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
    Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
    Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen.
    Mansour NM; Abdelaziz SA
    Microbiol Immunol; 2016 Aug; 60(8):527-32. PubMed ID: 27301486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an anti-streptococcal vaccine.
    García PC; Paillavil BA; Scioscia N; Dale JB; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM; Wozniak A
    Microbiol Immunol; 2018 Nov; 62(11):711-719. PubMed ID: 30357922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.